Abstract Background New oral anticoagulants (NOACs) offer an alternative to warfarin for
preventing stroke in patients with atrial fibrillation. NOACs are expected to replace warfarin …

Background Recent reports suggest altered antithrombotic efficacy and higher risk of
bleeding with new oral anticoagulants (NOACs) in patients with renal insufficiency. A meta …

Newer oral anticoagulants offer several advantages over traditional agents (eg warfarin), but
they are still associated with a bleeding risk and currently there is no validated reversal …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Background Atrial fibrillation (AF) is more likely to develop in patients with chronic kidney
disease (CKD) than in individuals with normal renal function, and patients with CKD are …

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in
clinical practice. One of its most devastating complications is the development of …

Aims To assess different aspects of the definition of valvular/non-valvular atrial fibrillation
(AF) used in clinical practice by physicians who usually treat this condition. Methods and …

Atrial fibrillation increases the risk of stroke, which is a leading cause of death and disability
worldwide. The use of oral anticoagulation in patients with atrial fibrillation at moderate or …

Background Atrial fibrillation (AF) is recognised as a growing clinical and public health
problem in many countries, owing to disability and death from stroke associated with the …

Chronic kidney disease (CKD) and atrial fibrillation (AF) frequently coexist. However, the
extent to which CKD increases the risk of thromboembolism in patients with nonvalvular AF …